SCHEMBL5542702

SCHEMBL5542702

[CH2]C/C=C/Nc1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.41
RAB9A P51151 6/20 0.41
NPC1 O15118 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
TP53 P04637 2/20 0.41
PKM P14618 1/20 0.41
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
STAT1 P42224 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 4/20 0.37
GAA P10253 2/20 0.37
APP P05067 1/20 0.37
SNCA P37840 1/20 0.37
BRCA1 P38398 1/20 0.37
TGM2 P21980 1/20 0.37
POLB P06746 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542705 1.00 MAPT (0.41) MAPTRAB9ANPC1SMN1; SMN2TP53
SCHEMBL5536330 0.79 TGM2 (0.42) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL5536333 0.79 TGM2 (0.42) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL5548450 0.78 ALDH1A1 (0.44) MAPTRAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL5548453 0.78 ALDH1A1 (0.44) MAPTRAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL14463322 0.73 KMT2A (0.37) MAPTRAB9ANPC1SMN1; SMN2TP53
SCHEMBL23513176 0.70 TGM2 (0.48) MAPTRAB9ANPC1SMN1; SMN2TP53
SCHEMBL16361384 0.68 KMT2A (0.41) MAPTRAB9ANPC1SMN1; SMN2TP53
SCHEMBL7428113 0.67 NFE2L2 (0.50) APP
SCHEMBL8548176 0.67 NFE2L2 (0.50) APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885RAB9A 2824/4885NPC1 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.